growth potential over the coming years. Moreover, the geriatric population possessing high
susceptibility for osteoporosis is further presumed to propel the high demand.
Osteoporosis Market Covers the Table of Contents With Segments, Key Players And Region. Based on
drug type, Osteoporosis Market is sub segmented into bisphosphonates, parathyroid hormone therapy,
calcitonin, selective estrogen inhibitors modulator (SERM) and rank ligand inhibitors. Bisphosphonates is
extensively used for prevention and treatment of osteoporosis, thus dominating the osteoporosis
treatment market.
Geographically, North America is the leading the global osteoporosis market, mainly due to increased
number suffering from osteoporosis. Technological advancements and increasing awareness about the
disease have also grown in this region. Increasing population in the Asia Pacific will also boost the
demand for osteoporosis market in the forecast period.
Major Players profiled in the Osteoporosis Market report incorporate: Aegis therapeutics, Amgen, Bone
medical, Chugai pharmaceutical, Eli lilly, Merck & co., Novartis pharma, Novo nordisk, Ranbaxy
laboratories and Osteologix.
Latest Industry News
1 Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and
Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of
osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone
builder with a unique dual effect that both increases bone formation and to a lesser extent reduces
bone resorption (or bone loss) to rapidly reduce the risk of fracture. A full course of EVENITY therapy is
12 monthly doses administered by a healthcare provider.2 Since osteoporosis is a chronic disease,
continued therapy with an anti-resorptive agent should be considered once EVENITY therapy is
completed.
MS neurologists in the United States, Canada, and Germany tested the tool with 198 patients with a
diagnosis of RRMS, SPMS or a suspected transition to SPMS. In the validation study, physicians went
through a series of weighted questions with the patients based on their experience in the last six
months. The questions aim to gather information on symptoms and how they impact daily life and
activities. Once completed, the algorithm generated a visual output that the physicians could use to
facilitate a discussion around the level of disease progression. The results from the validation study
demonstrated that MSProDiscussTM was able to differentiate between RRMS and SPMS patients with
high sensitivity and specificity and thus also inform about patients in transition.
One in two women will experience a fracture due to osteoporosis in her lifetime.1 These fractures can
be devastating, with many leading to hospital stays and life-altering consequences.3 The FDA approval
of EVENITY represents an important therapeutic development for patients who need a medicine that
can rapidly increase bone mineral density and help reduce the risk of future fractures within 12
months," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.